Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study

BACKGROUND: The 0.2 µg/day fluocinolone acetonide (FAc) implant delivers continuous, low-dose, intravitreal corticosteroid for the treatment of diabetic macular oedema (DMO). This ongoing, 3-year, observational clinical trial provides long-term, ‘real-world’ safety results for the FAc implant in DMO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Ophthalmol
Main Authors: Mansour, Sam E, Kiernan, Daniel F, Roth, Daniel B, Eichenbaum, David, Holekamp, Nancy M, Kaba, Samer, Werts, Erica
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical Science
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7907551/
https://ncbi.nlm.nih.gov/pubmed/32461262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjophthalmol-2020-315984
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados